GET IN TOUCH WITH US:

Click here to find out whatour clients think about ourSTRATEGY MEETINGS

ONLINE ONCOLOGYSTRATEGY MEETING USA 2020

3rd November 2020, Tuesday 9:00am - 2:00pm Pacific Time

UK: +44 (0)207 096 1222US: +44 (0)20 3314 0100 info@proventainternational.com www.proventainternational.com Connect with us

SPONSORS

AGENDA

KEYNOTE PRESENTATION

TRACK 1: Biomarker Discovery

TRACK 2: Precision Medicine / Personalised Medicine

TRACK 3: Companion Diagnostics

TRACK 4: Antibody Discovery, Antibody Drug Conjugates

TRACK 5: Immuno-oncology / Check Point Inhibitors

TRACK 6: Clinical Research

2019 ATTENDEES

CONTRIBUTORS TO THE AGENDA

Mahesh NarayananCEOPepVax

Yu LiangDirector, Translational Sciences, OncologyIpsen

Abhit SinghChief Regulatory OfficerIntrommune Therapeutics

Paul AgapowDirector Health InformaticsAstraZeneca

Achim KlessPain Genetics Lead, Discovery Neuroscience Research, Neuroscience GeneticsEli Lilly and Company Ltd

Ramon MohanlalExecutive Vice PresidentBeyondSpring Pharmaceuticals

Prasun MishraCEOAgility Pharma

Lore GruenbaumVP, Research Therapy Acceleration ProgramThe Leukemia & Lymphoma Society

OM SharmaSenior DirectorDSI

Geert C. MuddeFounder and CSOTYG oncology Ltd

06619e

OUR UNIQUE ONLINE MEETING FORMATRoundtable DiscussionsThese interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.

Personalised AgendaEach delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent on the online platform is focused and well-utilised.

One-to-one MeetingsThe most effective and time efficient way to assess potential partners at a strategic level. Gain access to our exclusive networking app to identify the people that you need to meet. The app will allow for instant and direct messaging to organise online meetings during the dedicated time to most benefit you.

Strategic NetworkingStrategic networking opportunities form a key benefit of the meeting. Our new online format for building and strengthening alliances to make lasting connections that benefit you.

OUR VISION

OUR MISSION

To be a platform for creating life-saving therapies and to facilitate the creation of a completely patient centric pharmaceutical industry.

By encouraging key leaders and their companies to put the patient at the very heart beat of every innovation. Sharing valuable insights and strategies to assist in the discovery, development and commercialisation of life saving therapies.

UK: +44 (0)207 096 1222US: +44 (0)20 3314 0100 info@proventainternational.com www.proventainternational.com

SPONSORSOUR

02GO TO MENU PREVIOUS PAGE NEXT PAGE

ONLINE ONCOLOGYSTRATEGY MEETING USA 2020

PRO-PARTNER

Cmed is an innovative, full service technology-led CRO. Cmed brings together experienced people and technology, providing customers with a friendly, proactive service, and delivers this service using advanced clinical data capture, management and reporting software and processes. Cmed’s new generation clinical data suite streamlines the capture, management and reporting of clinical data, saving customers time and money. Clinical data can be captured flexibly by eSource, multi-media and web eDC, while being displayed in live visual insights, providing live analytics, and allowing within suite audit trailed actions. It is fully compliant with regulatory guidelines, and allows integration with existing systems.

ONTOFORCE empowers data-driven decisions, drives innovation and speeds-up cycle time. We unlock and connect siloed data into a linked data fabric. This enables everyone to securely integrate, analyze, and extract data faster, bringing simplicity to complexity. With DISQOVER, ONTOFORCE developed an innovative, self-service, linked data platform that delivers trusted and timely insights for end users.

CO-HOST SPONSORSARENSIA EXPLORATORY MEDICINE is a German operator of proprietary Research Clinics in Eastern Europe, dedicated to performing complex Phase Ib, IIa and PROOF-OF-CONCEPT clinical trials with novel molecules, involving patients across numerous disease areas. Given the outstanding patient recruitment rates achieved by ARENSIA clinics, we are able to dramatically reduce the overall number of sites, countries and recruitment periods for any early phase patient trial. Sponsors regard the recruiting speed and the data quality of ARENSIA as disruptive added value, providing them with a strategic advantage. As a testament to the excellent performance, ARENSIA is trusted by the world’s largest pharmaceutical and biotechnology companies, by global CROs, as well as by venture capital funds aiming to maximize their return of investment in small/virtual biotech companies.

UK: +44 (0)207 096 1222US: +44 (0)20 3314 0100 info@proventainternational.com www.proventainternational.com

AGENDATRACK & ROOM

(TIME - Pacific Time) 01 - BIOMARKER DISCOVERY 02 - PRECISION MEDICINE / PERSONALISED MEDICINE

03 - COMPANION DIAGNOSTICS

04 - ANTIBODY DISCOVERY, ANTIBODY DRUG CONJUGATES

05 - IMMUNO-ONCOLOGY / CHECK POINT INHIBITORS 06 - CLINICAL RESEARCH

9:00am - 9:30am PT KEYNOTE PRESENTATION KEYNOTE PRESENTATION

9:30am - 9:45am PT BREAK

9:45am - 10:45am PT

Shifting Towards Protein-Based Diagnostic Biomarkers and Effectively Utilising Assays to Determine Genetic Mutations Yu Liang — Director, Translational Sciences, Oncology, Ipsen

Strategies to detect low levels of ctDNA in liquid biopsies Abhit Singh — Chief Regulatory Officer, Intrommune Therapeutics

Improving treatment efficacy and response rate through the optimization of companion diagnosis Karol Estrada — Director, Biomarin

Overcoming limitations of linkage and conjugation chemistry to link an optimized number of the payloads to the antibody in predefined location homogeneously. OM Sharma — Senior Director, DSI

Will we ever reach the goal of an allogeneic off-the-shelf T cell immunotherapy or should we be driving toward optimising autologous therapies? Ramon Mohanlal — Executive Vice President, BeyondSpring Pharmaceuticals

Increasing patient reach whilst maintaining retention for complex oncology trials and dealing with intense competition for patient populations Lore Gruenbaum — VP, Research Therapy Acceleration Program, The Leukemia & Lymphoma Society

10:45am - 11:00am PT BREAK

11:00am - 12:00pm PT

Strategies to Implement and Validate More Biomarkers from Discovery Into Clinical Practise Title TBC

Establishing a better understanding and utilization of correlations betweens non-genetic and genetic factors which contribute to different cancer phenotypes Title TBC

Strategies to increase clinical implementation of precision medicine companion diagnostics Title TBC

Selecting and optimising the most suited stable linkers and cytotoxic agents for ADC therapeutics Title TBC

Optimising autologous T cell immunotherapies - reducing vein-to-vein time and cost Title TBC

12:00pm - 12:15pm PT BREAK

12:15pm - 12:45pm PT KEYNOTE PRESENTATION KEYNOTE PRESENTATION

12:45pm - 1:00pm PT BREAK

1:00pm - 2:00pm PT

Integrating Multi-Omics Data With New in silico Technologies to Drive Biomarker Discovery Prasun Mishra — CEO, Agility Pharma

Increasing mutation detection rate in targeted therapies Mahesh Narayanan — CEO, PepVax

Improving CDx Assay Sensitivity to Detect Low Levels of Biomarkers

Discovering and Engineering Better Antibody Therapeutics Using Innovative in silico Technologies

With new innovations in immuno-oncology are checkpoint inhibitors a thing of the past? Sanjay Khare — President, Coherus Bioscience

How can we make oncology trials more systematic, streamlined and efficient whilst keeping the already high costs down George Naumov — COO, RS Oncology

END

03GO TO MENU PREVIOUS PAGE NEXT PAGE

ONLINE ONCOLOGYSTRATEGY MEETING USA 2020